MEI4 | Meiosis-specific 4 homolog (S. cerevisiae) | Predicted secreted proteins
| | | | | Tissue enhanced |
MFSD4 | Major facilitator superfamily domain containing 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
MME | Membrane metallo-endopeptidase | Cancer-related genes Candidate cardiovascular disease genes CD markers Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MMP24 | Matrix metallopeptidase 24 (membrane-inserted) | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
MRO | Maestro | | | | | | Tissue enhanced |
MT1F | Metallothionein 1F | | | | | | Tissue enhanced |
MT1H | Metallothionein 1H | | | | | | Tissue enhanced |
MT1HL1 | Metallothionein 1H-like 1 | | | | | | Tissue enhanced |
MTNR1A | Melatonin receptor 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
MYO3B | Myosin IIIB | Enzymes
| | | | | Tissue enhanced |
NELL1 | NEL-like 1 (chicken) | Predicted secreted proteins
| | | | | Tissue enhanced |
NPHS1 | Nephrosis 1, congenital, Finnish type (nephrin) | Disease related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
NPR3 | Natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C) | Predicted membrane proteins
| | | | | Tissue enhanced |
OGDHL | Oxoglutarate dehydrogenase-like | Citric acid cycle related proteins Mitochondrial proteins
| | | | | Tissue enhanced |
OTOGL | Otogelin-like | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
OXGR1 | Oxoglutarate (alpha-ketoglutarate) receptor 1 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PAH | Phenylalanine hydroxylase | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
PALM3 | Paralemmin 3 | | | | | | Tissue enhanced |
PAQR5 | Progestin and adipoQ receptor family member V | Predicted membrane proteins
| | | | | Tissue enhanced |
PARD6B | Par-6 family cell polarity regulator beta | | | | | | Tissue enhanced |
PCK1 | Phosphoenolpyruvate carboxykinase 1 (soluble) | Citric acid cycle related proteins Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
PCSK1N | Proprotein convertase subtilisin/kexin type 1 inhibitor | Predicted secreted proteins
| | | | | Tissue enhanced |
PDZK1 | PDZ domain containing 1 | | | | | | Tissue enhanced |
PDZK1IP1 | PDZK1 interacting protein 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
PKLR | Pyruvate kinase, liver and RBC | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
PLCXD2 | Phosphatidylinositol-specific phospholipase C, X domain containing 2 | | | | | | Tissue enhanced |
PNMA6A | Paraneoplastic Ma antigen family member 6A | | | | | | Tissue enhanced |
PNMA6B | Paraneoplastic Ma antigen family member 6B (pseudogene) | | | | | | Tissue enhanced |
PNMA6D | Paraneoplastic Ma antigen family member 6D (pseudogene) | | | | | | Tissue enhanced |
PODXL | Podocalyxin-like | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PRLR | Prolactin receptor | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PTGER1 | Prostaglandin E receptor 1 (subtype EP1), 42kDa | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
RANBP3L | RAN binding protein 3-like | | | | | | Tissue enhanced |
RBP5 | Retinol binding protein 5, cellular | Plasma proteins
| | | | | Tissue enhanced |
REN | Renin | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
RENBP | Renin binding protein | Enzymes
| | | | | Tissue enhanced |
RNF183 | Ring finger protein 183 | Predicted membrane proteins
| | | | | Tissue enhanced |
RNF224 | Ring finger protein 224 | | | | | | Tissue enhanced |
RP11-190A12.7 | Uncharacterized protein | | | | | | Tissue enhanced |
RP11-192H23.4 | Uncharacterized protein | | | | | | Tissue enhanced |
RP11-210M15.2 | Uncharacterized protein | | | | | | Tissue enhanced |
RP11-407N17.3 | CTAGE family member 5 isoform 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
RP4-583P15.14 | | | | | | | Tissue enhanced |
SALL1 | Spalt-like transcription factor 1 | Disease related genes Plasma proteins Transcription factors
| | | | | Tissue enhanced |
SALL3 | Spalt-like transcription factor 3 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
SCIN | Scinderin | Cytoskeleton related proteins Plasma proteins
| | | | | Tissue enhanced |
SCNN1G | Sodium channel, non-voltage-gated 1, gamma subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SFXN2 | Sideroflexin 2 | Mitochondrial proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SGK2 | Serum/glucocorticoid regulated kinase 2 | Enzymes
| | | | | Tissue enhanced |
SHISA3 | Shisa family member 3 | Predicted membrane proteins
| | | | | Tissue enhanced |